EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS

Sarah P Hudson-Phillips, Akriti Nanda, Mohamed Attia, Wadha Al Yaqout, Evelyn Marshall, Jennifer E Rusby, Katherine Krupa, Peter A Barry, Marios Konstantinos Tasoulis, Gerald Gui, Radhika Merh, Bethany Torr und 4 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.07.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Sarah P Hudson-Phillips und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Royal Marsden Hospital, London, UK. Electronic address: s.hudson-phillips@nhs.net. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing, Germ-Line Mutation, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Approximately 3% of patients with breast cancer have an inherited pathogenic variant in high-penetrance genes such as BRCA1, BRCA2 or PALB2. Knowledge of genetic testing result may impact surgery undertaken at the time of index breast cancer treatment. The aim of this study was to evaluate the impact of a positive high penetrance genetic test (HPGT) on surgical decision-making. METHODS: Females >18 years diagnosed with invasive breast cancer or high-grade Ductal carcinoma in situ (DCIS) without prior BRCA-gene testing were included. In patients with a germline pathogenic variant (GPV) further data on surgical decision-making were collected. RESULTS: Five hundred seventy-six patients were included. Median time from consent to result was 33 days (inter-quartile range 25-45). GPV rate was 3.6% (21/576): 11 BRCA1 (1.9%), 6 BRCA2 (1%), 4 PALB2 (0.7%). Five (23.8%) of 21 patients with GPV would not have been eligible for HPGT on the UK National Health Service R208 pathway. Four hundred eighty (83.3%) of the 576 patients underwent primary breast cancer surgery; 121 (25.2%) of 480 patients received results pre-operatively, 359 (74.8%) post-operatively. Pre-operative GPV knowledge significantly influenced the initial surgical procedure undertaken (P = .002). Uptake of subsequent risk-reducing surgery was higher with a preoperative result (100% vs. 71.4%), although this difference was not statistically significant (P = .24). CONCLUSIONS: Early timing of positive HPGT results significantly influences surgical decision-making and increases pre-operative uptake of bilateral risk-reducing mastectomy. Expanded HPGT access in this study identified 24% additional patients with GPV who would not have met current UK testing criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenetic TestingGerm-Line MutationCarcinoma, Intraductal, NoninfiltratingPenetranceCarcinoma, Ductal, BreastHumansFemaleMiddle AgedAdultAgedFanconi Anemia Complementation Group N ProteinGenetic Predisposition to DiseaseBRCA1 ProteinBRCA2 ProteinMastectomy

Stichwörter der Autor:innen

BRCA1/2Ductal carcinoma in situMainstreamingPALB2Surgical decision-making

Substanzen

PALB2 protein, humanFanconi Anemia Complementation Group N ProteinBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Department of Breast Surgery, The Royal Marsden Hospital, London, UK. Electronic address: s.hudson-phillips@nhs.net.
  • Department of Breast Surgery, The Royal Marsden Hospital, London, UK.
  • Department of Breast Surgery, The Royal Marsden Hospital, London, UK; Department of General Surgery, Cairo University Hospitals, Cairo, Egypt.
  • Department of Breast Surgery, The Royal Marsden Hospital, London, UK; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Department of Breast Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Zitieren

APA

Hudson-Phillips, S. P., Nanda, A., Attia, M., Al Yaqout, W., Marshall, E., Rusby, J. E., Krupa, K., Barry, P. A., Tasoulis, M. K., Gui, G., Merh, R., Torr, B., Kemp, Z., George, A., Turnbull, C., & O'Connell, R. L. (2026). The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.031

Vancouver

Hudson-Phillips SP, Nanda A, Attia M, Al Yaqout W, Marshall E, Rusby JE, et al. The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.031

BibTeX
@article{HudsonPhillips2026,
  author = {Hudson-Phillips, Sarah P and Nanda, Akriti and Attia, Mohamed and Al Yaqout, Wadha and Marshall, Evelyn and Rusby, Jennifer E and Krupa, Katherine and Barry, Peter A and Tasoulis, Marios Konstantinos and Gui, Gerald and Merh, Radhika and Torr, Bethany and Kemp, Zoe and George, Angela and Turnbull, Clare and O'Connell, Rachel L},
  title = {The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.07.031}
}
Kostenlos starten →